Bank Julius Baer & Co. Ltd, Zurich Prelude Therapeutics Inc Transaction History
Bank Julius Baer & Co. Ltd, Zurich
- $29.1 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding PRLD
# of Institutions
59Shares Held
30.4MCall Options Held
6.4KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$8.73 Million0.38% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$8.1 Million0.14% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$855,1320.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.03MShares$823,3590.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$808,3130.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $29.1M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...